Individuals with Familial Hypercholesterolaemia (FH) are at very high risk of cardiovascular disease, which is associated with poor outcomes from coronavirus infections. COVID-19 puts strain on healthcare systems and may impair access to routine FH services. On behalf of the International Lipid Expert Panel (ILEP) and the European FH Patient Network (FH Europe), we present brief recommendations on the management of adult patients with FH during the COVID-19 pandemic. We discuss the implications of COVID-19 infections for FH patients, the importance of continuing lipid-lowering therapy where possible, issues relating to safety monitoring and service delivery. We summarise the evidence for additional benefits of statins and other lipid-lowering drugs during viral infections. The recommendations do not override in any way the individual responsibility of physicians to make appropriate and accurate decisions taking into account the condition of a given patient and the doses, rules, and regulations applicable to drugs and devices at the time of their prescription/use.

3rd Department of Internal Medicine 1st Faculty of Medicine Charles University and General Faculty Hospital Prague Prague Czech Republic

Baqiyatallah Hospital Baqiyatallah University of Medical Sciences Tehran Iran

Biotechnology Research Center Pharmaceutical Technology Institute Mashhad University of Medical Sciences Mashhad Iran; Neurogenic Inflammation Research Center Mashhad University of Medical Sciences Mashhad Iran; School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran

Department of Cardiology Ege Üniversitesi School of Medicine Izmir Turkey

Department of Cardiology of the East Slovak Institute of Cardiovascular Disease and Faculty of Medicine PJ Safarik University Kosice Slovak Republic

Department of Hypertension Chair of Nephrology and Hypertension Medical University of Lodz Poland; Polish Mother's Memorial Hospital Research Institute Lodz Poland; Cardiovascular Research Centre University of Zielona Gora Zielona Gora Poland

Department of Internal Diseases University Hospital Center Zagreb School of Medicine Zagreb University Zagreb Croatia

Division of Medicine Centre for Preventive Cardiology University Medical Centre Ljubljana Medical Faculty University of Ljubljana Ljubljana Slovenia

FH Europe Europe

School of Pharmacy and Biomolecular Sciences Liverpool John Moores University Liverpool UK

Zobrazit více v PubMed

EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz A.J., De Marco M., Stevens C.A.T., Akram A., Freiberger T., Hovingh G.K., Kastelein J.J.P., Mata P., Raal F.J., Santos R.D., Soran H., Watts G.F., Abifadel M., Aguilar-Salinas C.A., Al-Khnifsawi M., AlKindi F.A., Alnouri F., Alonso R., Al-Rasadi K., Al-Sarraf A., Ashavaid T.F., Binder C.J., Bogsrud M.P., Bourbon M., Bruckert E., Chlebus K., Corral P., Descamps O., Durst R., Ezhov M., Fras Z., Genest J., Groselj U., Harada-Shiba M., Kayikcioglu M., Lalic K., Lam C.S.P., Latkovskis G., Laufs U., Liberopoulos E., Lin J., Maher V., Majano N., Marais A.D., März W., Mirrakhimov E., Miserez A.R., Mitchenko O., Nawawi H.M., Nordestgaard B.G., Paragh G., Petrulioniene Z., Pojskic B., Postadzhiyan A., Reda A., Reiner Ž., Sadoh W.E., Sahebkar A., Shehab A., Shek A.B., Stoll M., Su T.C., Subramaniam T., Susekov A.V., Symeonides P., Tilney M., Tomlinson B., Truong T.H., Tselepis A.D., Tybjærg-Hansen A., Vázquez-Cárdenas A., Viigimaa M., Vohnout B., Widén E., Yamashita S., Banach M., Gaita D., Jiang L., Nilsson L., Santos L.E., Schunkert H., Tokgözoğlu L., Car J., Catapano A.L., Ray K.K., EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Atherosclerosis. 2018;277:234–255. PubMed

https://www.worldometers.info/coronavirus/. (Last accessed: 1st May 2020).

https://www.worldometers.info/coronavirus/coronavirus-age-sex-demographics/. (Last accessed: 1st May 2020).

U.S. Centers for Disease Control and Prevention; 2020. Coronavirus Disease 2019 (COVID-2019)https://www.cdc.gov/coronavirus/2019-ncov/index.html (Last accessed 30 March 2020)

Vallejo-Vaz A.J., Kondapally Seshasai S.R., Cole D., Hovingh G.K., Kastelein J.J., Mata P., Raal F.J., Santos R.D., Soran H., Watts G.F., Abifadel M., Aguilar-Salinas C.A., Akram A., Alnouri F., Alonso R., Al-Rasadi K., Banach M., Bogsrud M.P., Bourbon M., Bruckert E., Car J., Corral P., Descamps O., Dieplinger H., Durst R., Freiberger T., Gaspar I.M., Genest J., Harada-Shiba M., Jiang L., Kayikcioglu M., Lam C.S., Latkovskis G., Laufs U., Liberopoulos E., Nilsson L., Nordestgaard B.G., O’Donoghue J.M., Sahebkar A., Schunkert H., Shehab A., Stoll M., Su T.C., Susekov A., Widén E., Catapano A.L., Ray K.K. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis. 2015;243(1):257–259. PubMed

Bianconi V., Banach M., Pirro M., International Lipid Expert Panel (ILEP) Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc. Med. 2020 doi: 10.1016/j.tcm.2020.03.004. PubMed DOI

Solnica B., Sygitowicz G., Sitkiewicz D., Cybulska B., Jóźwiak J., Odrowąż-Sypniewska G., Banach M. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Arch. Med. Sci. 2020;16(2):237–252. PubMed PMC

Banach M., Penson P.E. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc. Res. 2019;115(3):e26–e31. PubMed

Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M.R., Tokgozoglu L., Wiklund O., ESC Scientific Document GrouP 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020;41(1):111–188. PubMed

Katsiki N., Banach M., Mikhailidis D.P. Lipid lowering therapy and Renin-Angiotensin-Aldosterone System Inhibitors in the era of the COVID-19 pandemic. Arch. Med. Sci. 2020;16(3):485–489. PubMed PMC

Ridker P.M. Clinician’s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J. Am. Coll. Cardiol. 2018;72(25):3320–3331. PubMed

Momtazi-Borojeni A.A., Sabouri-Rad S., Gotto A.M. PCSK9 and inflammation: a review of experimental and clinical evidence. Eur. Heart J. Cardiovasc. Pharmacother. 2019;5(4):237–245. PubMed

Guo T., Fan Y., Chen M. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1017. PubMed DOI PMC

Leipold R., Raal F., Ishak J., Hovingh K., Phillips H. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis. Eur. J. Prev. Cardiol. 2017;24(17):1843–1850. PubMed

McMichael T.M., Currie D.W., Clark S. Epidemiology of Covid-19 in a long-term care facility in king county, Washington. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2005412. PubMed DOI PMC

Guo H., Huang M., Yuan Q. The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain. PLoS One. 2017;12(1) PubMed PMC

Jeon J.H., Lee C. Cholesterol is important for the entry process of porcine deltacoronavirus. Arch. Virol. 2018;163(11):3119–3124. PubMed PMC

South A.M., Diz D.I., Chappell M.C. COVID-19, ACE2, and the cardiovascular consequences. Am. J. Physiol. Heart Circ. Physiol. 2020;318(5):H1084–H1090. PubMed PMC

Reiner Ž, Hatamipour M., Banach M. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch. Med. Sci. 2020;16(3):490–496. PubMed PMC

Driggin E., Madhavan M.V., Bikdeli B., Chuich T., Laracy J., Bondi-Zoccai G., Brown T.S., Nigoghossian C., Zidar D.A., Haythe J., Brodie D., Beckman J.A., Kirtane A.J., Stone G.W., Krumholz H.M., Parikh S.A. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J. Am. Coll. Cardiol. 2020;75(18):2352–2371. doi: 10.1016/j.jacc.2020.03.031. PubMed DOI PMC

Stockley’s Drug Interactions: azithromycin and statins interactions: https://about.medicinescomplete.com/publication/stockleys-interactions-checker/. (Last accessed 1st May 2020).

Rosenson R.S., Baker S., Banach M. Optimizing cholesterol treatment in patients with muscle complaints. J. Am. Coll. Cardiol. 2017;70(10):1290–1301. PubMed

https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring-adressed_en-2.pdf. (Last accessed 6th April 2020).

https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf. (Last Accessed 6th April 2020).

Nikolic D., Banach M., Chianetta R., Luzzu L.M., Pantea Stoian A., Diaconu C.C., Citarrella R., Montalto G., Rizzo M. An overview of statin-induced myopathy and perspectives for the future. Expert Opin. Drug Saf. 2020;19(5):601–615. doi: 10.1080/14740338.2020.1747431. PubMed DOI

Vuorio A., Watts G.F., Kovanen P.T. Familial hypercholesterolaemia and COVID‐19: triggering of increased sustained cardiovascular risk. J. Intern. Med. 2020 doi: 10.1111/joim.13070. PubMed DOI